Literature DB >> 23800548

Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging.

Michael D Nelson1, Ronald G Victor, Edward W Szczepaniak, Vinaya Simha, Abhimanyu Garg, Lidia S Szczepaniak.   

Abstract

Generalized lipodystrophy is a rare disorder characterized by marked loss of adipose tissue with reduced triglyceride storage capacity, leading to a severe form of metabolic syndrome including hypertriglyceridemia, insulin resistance, type 2 diabetes mellitus, and hepatic steatosis. Recent echocardiographic studies suggest that concentric left ventricular (LV) hypertrophy is another characteristic feature of this syndrome, but the mechanism remains unknown. It has recently been hypothesized that the LV hypertrophy could be an extreme clinical example of "lipotoxic cardiomyopathy": excessive myocyte accumulation of triglyceride leading to adverse hypertrophic signaling. To test this hypothesis, the first cardiac magnetic resonance study of patients with generalized lipodystrophy was performed, using magnetic resonance imaging and localized proton spectroscopy to detect excessive triglyceride content in the hypertrophied myocytes. Six patients with generalized lipodystrophy and 6 healthy controls matched for age, gender, and body mass index were studied. As hypothesized, myocardial triglyceride content was threefold higher in patients than controls: 0.6 ± 0.2% versus 0.2 ± 0.1% (p = 0.004). The presence of pericardial fat was also found, representing a previously undescribed adipose depot in generalized lipodystrophy. Patients with generalized lipodystrophy, compared with controls, also had a striking degree of concentric LV hypertrophy, independent of blood pressure: LV mass index 101.0 ± 18.3 versus 69.0 ± 17.7 g/m(2), respectively (p = 0.02), and LV concentricity 1.3 ± 0.3 versus 0.99 ± 0.1 g/ml, respectively (p = 0.04). In conclusion, these findings advance the lipotoxicity hypothesis as a putative underlying mechanism for the dramatic concentric LV hypertrophy found in generalized lipodystrophy.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23800548      PMCID: PMC3779507          DOI: 10.1016/j.amjcard.2013.05.036

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1975.

Authors: 
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

2.  Liporegulation in diet-induced obesity. The antisteatotic role of hyperleptinemia.

Authors:  Y Lee; M Y Wang; T Kakuma; Z W Wang; E Babcock; K McCorkle; M Higa; Y T Zhou; R H Unger
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

3.  Relation between epicardial adipose tissue and left ventricular mass.

Authors:  Gianluca Iacobellis; Maria Cristina Ribaudo; Alessandra Zappaterreno; Concetta Valeria Iannucci; Frida Leonetti
Journal:  Am J Cardiol       Date:  2004-10-15       Impact factor: 2.778

4.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

5.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.

Authors:  Brian N Finck; John J Lehman; Teresa C Leone; Michael J Welch; Michael J Bennett; Attila Kovacs; Xianlin Han; Richard W Gross; Ray Kozak; Gary D Lopaschuk; Daniel P Kelly
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 6.  Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart.

Authors:  Brian N Finck; Daniel P Kelly
Journal:  J Mol Cell Cardiol       Date:  2002-10       Impact factor: 5.000

7.  Bulk magnetic susceptibility effects on the assessment of intra- and extramyocellular lipids in vivo.

Authors:  Lidia S Szczepaniak; Robert L Dobbins; Daniel T Stein; J Denis McGarry
Journal:  Magn Reson Med       Date:  2002-03       Impact factor: 4.668

8.  A novel mouse model of lipotoxic cardiomyopathy.

Authors:  H C Chiu; A Kovacs; D A Ford; F F Hsu; R Garcia; P Herrero; J E Saffitz; J E Schaffer
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

9.  Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.

Authors:  Zahid Ahmad; Lalitha Subramanyam; Lidia Szczepaniak; Vinaya Simha; Beverley Adams-Huet; Abhimanyu Garg
Journal:  Eur J Endocrinol       Date:  2013-04-15       Impact factor: 6.664

Review 10.  Lipodystrophies: rare disorders causing metabolic syndrome.

Authors:  Abhimanyu Garg; Anoop Misra
Journal:  Endocrinol Metab Clin North Am       Date:  2004-06       Impact factor: 4.741

View more
  34 in total

1.  1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes.

Authors:  Francesco Secchi; Giovanni Di Leo; Marcello Petrini; Riccardo Spairani; Marco Alì; Marco Guazzi; Francesco Sardanelli
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

2.  Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women.

Authors:  Janet Wei; Michael D Nelson; Edward W Szczepaniak; Laura Smith; Puja K Mehta; Louise E J Thomson; Daniel S Berman; Debiao Li; C Noel Bairey Merz; Lidia S Szczepaniak
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-30       Impact factor: 4.733

Review 3.  Imaging body fat: techniques and cardiometabolic implications.

Authors:  H Wang; Y E Chen; Daniel T Eitzman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-21       Impact factor: 8.311

Review 4.  How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative.

Authors:  Fuki M Hisama; Junko Oshima; George M Martin
Journal:  Cold Spring Harb Perspect Med       Date:  2016-04-01       Impact factor: 6.915

5.  Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy.

Authors:  Hongyi Zhou; Xinnuo Lei; Yun Yan; Todd Lydic; Jie Li; Neal L Weintraub; Huabo Su; Weiqin Chen
Journal:  JCI Insight       Date:  2019-06-11

6.  Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy.

Authors:  Michael D Nelson; Lidia S Szczepaniak; Troy M LaBounty; Edward Szczepaniak; Debiao Li; Mourad Tighiouart; Quanlin Li; Rohan Dharmakumar; Gregg Sannes; Zhaoyang Fan; Roya Yumul; W David Hardy; Antonio Hernandez Conte
Journal:  JACC Cardiovasc Imaging       Date:  2014-11-10

7.  Obesity-related cardiomyopathy is an adipocyte-mediated paracrine disease.

Authors:  Jane A Leopold
Journal:  Trends Cardiovasc Med       Date:  2014-10-02       Impact factor: 6.677

8.  Obesity-associated cardiac dysfunction in starvation-selected Drosophila melanogaster.

Authors:  Christopher M Hardy; Ryan T Birse; Matthew J Wolf; Lin Yu; Rolf Bodmer; Allen G Gibbs
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-07-01       Impact factor: 3.619

9.  Adipose tissue mitochondrial dysfunction triggers a lipodystrophic syndrome with insulin resistance, hepatosteatosis, and cardiovascular complications.

Authors:  Cecile Vernochet; Federico Damilano; Arnaud Mourier; Olivier Bezy; Marcelo A Mori; Graham Smyth; Anthony Rosenzweig; Nils-Göran Larsson; C Ronald Kahn
Journal:  FASEB J       Date:  2014-07-08       Impact factor: 5.191

10.  Relationship Between Left Ventricular Structural and Metabolic Remodeling in Type 2 Diabetes.

Authors:  Eylem Levelt; Masliza Mahmod; Stefan K Piechnik; Rina Ariga; Jane M Francis; Christopher T Rodgers; William T Clarke; Nikant Sabharwal; Jurgen E Schneider; Theodoros D Karamitsos; Kieran Clarke; Oliver J Rider; Stefan Neubauer
Journal:  Diabetes       Date:  2015-10-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.